Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation

Pflugers Arch. 2003 Aug;446(5):559-71. doi: 10.1007/s00424-003-1077-0. Epub 2003 Jul 1.

Abstract

Voltage-gated K+ currents expressed in two rat prostate cancer ("Dunning") cell lines of markedly different metastatic ability were characterised using electrophysiological, pharmacological and molecular approaches. Whole-cell patch-clamp recordings showed that both strongly metastatic MAT-LyLu and weakly metastatic AT-2 cell lines possessed outward (delayed-rectifier type) K+ currents, which activated at around -40 mV. From the parameters measured, several characteristics of the two cell lines were similar. However, a number of statistically significant differences were noted for MAT-LyLu versus the AT-2 cells as follows: (1) current densities were smaller; (2) the slope factor for channel activation was smaller; (3) the voltage at which current was half-inactivated, and the slope factor for channel inactivation were greater; (4) the time constants for current decay at -20 and 0 mV were smaller; and (5) the residual peak current was larger following 60 s of repetitive voltage pulses for stimulation frequencies in the range 0.05-0.2 Hz. On the other hand, the K+ currents in both cell lines showed similar pharmacological profiles. Thus, the currents were blocked by 4-aminopyridine, tetraethylammonium, verapamil, margatoxin, and charybdotoxin, with highly similar IC(50)s for given blockers. The electrophysiological and pharmacological data taken together suggested expression of voltage-gated K+ channels of the Kv1 family, expression of the Kv1.3 subunit being predominant. Western blot and RT-PCR tests both confirmed that the cells indeed expressed Kv1.3 and to a lesser extent Kv1.4 and Kv1.6 channel alpha-subunits. In view of the similarity of channel expression in the two cell lines, voltage-gated K+ channel activity may not be a primary determinant of metastatic potential in the rat model of prostate cancer, but the possible contribution of K+ channel activity to the metastatic process is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Animals
  • Blotting, Western
  • Calcium Channel Blockers / pharmacology*
  • Cell Line, Tumor / physiology
  • Charybdotoxin / pharmacology
  • Gene Expression Regulation, Neoplastic
  • Kv1.3 Potassium Channel
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Molecular Sequence Data
  • Neurotoxins / pharmacology
  • Patch-Clamp Techniques
  • Potassium / metabolism
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / genetics*
  • Potassium Channels / metabolism*
  • Potassium Channels, Voltage-Gated*
  • Prostatic Neoplasms*
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction
  • Scorpion Venoms
  • Tetraethylammonium / pharmacology
  • Verapamil / pharmacology

Substances

  • Calcium Channel Blockers
  • Kcna3 protein, rat
  • Kv1.3 Potassium Channel
  • Neurotoxins
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Voltage-Gated
  • Scorpion Venoms
  • Charybdotoxin
  • margatoxin
  • Tetraethylammonium
  • 4-Aminopyridine
  • Verapamil
  • Potassium

Associated data

  • GENBANK/AJ276135
  • GENBANK/AJ276136
  • GENBANK/AJ276137
  • GENBANK/AJ276138